Middle East Pharmaceutical Industries Company

Middle East Pharmaceutical Industries Company (4016) is a Saudi-based manufacturer of specialty and generic drugs. The company develops, produces, and markets a wide range of pharmaceutical products, including branded generics, over-the-counter (OTC) medicines, and specialized therapeutic solutions. Its portfolio covers key therapeutic areas such as cardiology, gastroenterology, neurology, and anti-infectives. The company operates under strict regulatory standards and focuses on high-quality, affordable medications for the regional market.

The company generates revenue primarily through the sale of pharmaceutical products to wholesalers, hospitals, pharmacies, and government healthcare institutions. Its business model relies on a mix of in-house R&D, licensing agreements, and strategic partnerships to expand its product pipeline. Revenue is driven by both prescription drugs and OTC products, with a growing emphasis on high-margin specialty generics. The company's recent financial performance shows strong revenue growth of 33.65% year-over-year, supported by expanding market share and new product launches.

As a player in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry, the company competes with other regional and multinational pharmaceutical firms. Its competitive positioning is strengthened by a solid gross margin of 62.29% and an operating margin of 23.74%, indicating efficient cost management and pricing power. The company's moderate debt level (82.97M SAR) and healthy cash position (13.40M SAR) provide financial flexibility. With a PE ratio of 12.14 and EV/EBITDA of 9.59, the company is valued reasonably compared to peers.

The company's primary customers are healthcare providers, including hospitals, clinics, and pharmacies, as well as patients who purchase OTC products. Its target audience spans both private and public healthcare sectors in Saudi Arabia and potentially other Middle Eastern markets. The company focuses on serving the growing demand for affordable, high-quality generic drugs in the region, capitalizing on the Saudi government's healthcare expansion initiatives and the trend towards localized pharmaceutical production.

An auto-generated descriptive profile based on company data, for informational purposes only.